Alx Oncology Holdings Inc (ALXO) concluded trading on Thursday at a closing price of $1.63, with 6.34 million shares of worth about $10.33 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -75.49% during that period and on January 23, 2025 the price saw a loss of about -9.44%. Currently the company’s common shares owned by public are about 52.74M shares, out of which, 30.92M shares are available for trading.
Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of 10.14%. Year-to-date (YTD), ALXO shares are showing a performance of -2.40% which decreased to -87.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.19 but also hit the highest price of $17.83 during that period. The average intraday trading volume for Alx Oncology Holdings Inc shares is 1.03 million. The stock is currently trading -5.07% below its 20-day simple moving average (SMA20), while that difference is up 3.13% for SMA50 and it goes to -69.79% lower than SMA200.
Alx Oncology Holdings Inc (NASDAQ: ALXO) currently have 52.74M outstanding shares and institutions hold larger chunk of about 55.64% of that.
The stock has a current market capitalization of $85.97M and its 3Y-monthly beta is at 0.99. It has posted earnings per share of -$2.98 in the same period. It has Quick Ratio of 4.82 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALXO, volatility over the week remained 11.52% while standing at 11.21% over the month.
Analysts are in expectations that Alx Oncology Holdings Inc (ALXO) stock would likely to be making an EPS of -0.39 in the current quarter, while forecast for next quarter EPS is -0.82 and it is -2.28 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.39 which is -0.39 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.79 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 26.31% while it is estimated to increase by 9.14% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on December 19, 2024 offering a Hold rating for the stock and assigned a target price range of between $12 and $2 to it. Coverage by Stifel stated Alx Oncology Holdings Inc (ALXO) stock as a Hold in their note to investors on March 08, 2024, suggesting a price target of $14 for the stock. On December 08, 2023, Jefferies Upgrade their recommendations, while on December 22, 2021, Jefferies Downgrade their ratings for the stock with a price target of $25. Stock get a Buy rating from Stifel on September 30, 2021.
